Lupin launches generic Levothyroxine Sodium Tablets USP
Deepthi | Myequity news | Date : 22-03-2019 12:48:00 IST
Lupin Limited announced the launch of Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid® Tablets. It is indicated for:
- Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
- Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer
Levothyroxine Sodium Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg had an annual sales of approximately USD 2.5 billions in the U.S (IQVIA MAT January 2019). About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.